WEEK 152 DATA FROM THE SELECT|PSA 1 AND SELECT|PSA 2 ...

WEEK 152 DATA FROM THE SELECT-PSA 1 AND SELECT-PSA 2 ...

PsA who were non–bDMARD-IR or bDMARD-IR largely sustained wk 24 responses, achieving durable disease control with UPA15 through nearly 3 years of treatment.

Upadacitinib in patients with psoriatic arthritis and inadequate ...

... 152 weeks of treatment in this highly treatment-refractory population of patients with PsA ... Philip Mease , Arathi Setty , Kim Papp ...

WEEK 152 DATA FROM THE SELECT-PSA 1 AND ... - ResearchGate

Request PDF | POS0945 SUSTAINABILITY OF RESPONSE WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE PSORIATIC ARTHRITIS: WEEK ...

Upadacitinib in Patients with Psoriatic Arthritis and Inadequate ...

... 1 biologic disease-modifying anti-rheumatic drugs. The purpose of this 56-week analysis of SELECT-PsA 2 data was to explore the longer-term safety and ...

3-YEAR RESULTS FROM THE PHASE 3 SELECT-PsA 1 STUDY

... week (wk) 104 or 2 years of treatment in SELECT-PsA 1. Objectives To evaluate efficacy and safety of UPA vs adalimumab (ADA) through wk 152 or 3 years ...

Achievement of Disease Control in PsA Patients Treated with ...

... week (wk) 152 from two phase 3 trials. Methods: Post hoc analysis of pts from the SELECT-PsA 1 (N=1704; inadequate response to non-biologic DMARDs [non ...

AbbVie Presents Long-Term Data Further Supporting the Efficacy ...

- One-year efficacy and safety data of RINVOQ are reported in SELECT ... week 14, from the Phase 3 SELECT-AXIS 2 program. Efficacy endpoints ...

Upadacitinib in patients with psoriatic arthritis and inadequate ...

Here we present efficacy and safety data from patients who completed up to 152 weeks of upa- dacitinib treatment in SELECT-PsA 2, including a subanalysis of ...

Efficacy of Upadacitinib Maintained for 3 Years for Those With ...

Previously, upadacitinib improved symptoms through 2 years in the SELECT-PsA 1 trial for those with psoriatic arthritis with prior ...

Results Possible with RINVOQ® (upadacitinib) for active PsA

... weeks).†. Helps relieve PsA pain, swelling, and stiffness in 2 weeks, 12 weeks,. Individual results may vary. Relief at 3 years (152 weeks †). Of those who ...

HUMIRA® (adalimumab) for Psoriatic Arthritis (PsA)

EFFICACY; SAFETY. Radiographic progression: 48 weeks1-3. MEAN CHANGE FROM BASELINE IN mTSS. RCTOLE. Co-primary endpoint. -1 0 1 2 3 4 WEEK 24 WEEK 48 0.9 -0.1 - ...

Effect of bimekizumab on symptoms and impact of disease in ...

Data from Weeks 0–152 are presented using the full analysis set of the phase 2b study (N = 206), consisting of all randomised patients who ...

psoriatic-arthritis-mda-flashcard.pdf - rinvoq hcp

SELECT-PSA 2 STUDY DESIGN:¹ 24-week, double-blind, placebo-controlled ... analysis of the randomized, placebo-controlled SELECT-PsA 1 and 2 phase 3 trials.

Clinical Study Protocol M15-572 A Phase 3, Randomized, Double ...

treatment of PsA are prohibited during the study (Period 1 and Period 2). ... Subjects who complete the last visit of Period 2 (Week 152) will ...

Upadacitinib as monotherapy and in combination with non-biologic ...

... 2 [10]. UPA has been assessed for the treatment of PsA in two global phase 3 trials, SELECT-PsA 1 and SELECT-PsA 2 [11, 12]. In both of ...

Bimekizumab safe and effective for AS and PsA in long-term trials

... week 48, 65% at week 152). Credit: V. Summersby/Springer Nature Limited. In the BE AGILE study, 303 adults with active AS were enrolled in a ...

New BIMZELX[®] (bimekizumab-bkzx) data at ACR Convergence ...

Bimekizumab-bkzx two-year data in PsA presented at ACR Convergence 2024: ... 1 and 2, respectively, 494 patients entered BE MOVING at Week 52.3.

Bimekizumab in patients with psoriatic arthritis, naive to biologic ...

... 2 BE ACTIVE study subgroup data and published data from other interventions. ... Two malignancies occurred by week 16, one (<1%) in a patient ...

SELECT-PsA 1 and SELECT-PsA 2 Extended Trial Results Show ...

Virtual Meeting – The extended 56-week data from two pivotal phase 3 trials with a new generation JAK inhibitor for the control of psoriatic ...

Full article: Bimekizumab for the treatment of psoriatic arthritis

1. 1.1. Psoriatic arthritis (PsA) is a persistent, inflammatory disease associated with diverse manifestations across the joints and skin, ...